ArticleEuropean journal of nuclear medicine and molecular imaging2026
Combination therapy of an
Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Macropa-Based 225Ac-Labeled RGD Peptides for Targeted Alpha Therapy.Molecular pharmaceutics · 2026Article
- Engineering intrinsically radiolabeled nanoparticles for imaging and therapy: a decade of design strategies and insights.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeRecently, an 211At-labeled RGD peptide with an albumin-binding moiety, Ga-DOTA-K([211At]APBA)-c(RGDfK) ([211At]1), was developed for targeted alpha therapy and radiotheranostics. [211At]1 showed high tumor accumulation and inhibited tumor growth in a dose-dependent manner. This study aimed to investigate whether [211At]1 can induce an antitumor immune response and whether the combination of [211At]1 and immune checkpoint blockade can enhance therapeutic efficacy.
methodsBiodistribution experiments of [211At]1 and therapeutic experiments of [211At]1 with or without anti-PD-1 or anti-CTLA-4 antibody were conducted in Colon-26 tumor-bearing BALB/c mice. Additionally, therapeutic experiments of [211At]1 were conducted in Colon-26 tumor-bearing BALB/c nu/nu mice to confirm the difference in the therapeutic effects derived from antitumor immune responses of [211At]1. Infiltration of antitumor immune activity in Colon-26 tumors was confirmed by flow cytometry and immunofluorescence staining.
results[211At]1 showed high tumor accumulation and inhibited tumor growth in a dose-dependent manner in Colon-26 tumor-bearing BALB/c mice. Additionally, mice treated with [211At]1 (675 kBq) and anti-CTLA-4 antibody showed superior tumor growth inhibition compared with mice treated with only [211At]1 (675 kBq). Tumor growth inhibition was weaker in BALB/c nu/nu mice than in BALB/c mice. Infiltration of CD4+ and CD8+ T cells was observed following treatment with [211At]1 (675 kBq) alone or in combination with anti-CTLA-4 antibody.
conclusion[211At]1 induced an antitumor immune response and enhanced the therapeutic efficacy. The combination of [211At]1 and immune checkpoint blockade agents could be promising for cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.